Objective Response
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Irinotecan and Anlotinib for Epithelioid Sarcoma (NCT05656222) | Peking University People's Hospital | 2021-08-01 |
| NAC Followed by RH for the Treatment of LACC (NCT03963882) | Lei Li | 2019-06-19 |
Track Objective Response automatically
Every clearance here is in the API, with alerts when new ones post.